Nashat Rabadi, MD
Pulmonary Disease · Buffalo, NYNPI 1669421970
Payments from drug & device makers
Across 986 payments — averaging $621.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$233K
- Boehringer Ingelheim$126K
- Regeneron Healthcare Solutions, Inc.$111K
- Mylan Specialty L.p.$54K
- Grifols USA, LLC$49K
- Sunovion Pharmaceuticals Inc.$14K
- plus $26K from 21 others
What the payments were for
- Consulting fees$27,1194%
- Speaking & faculty fees$509,27183%
- Travel & lodging$48,9188%
- Food & beverage$27,4994%
- Education$2440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 271 | $232,556 |
| Boehringer Ingelheim | 218 | $126,023 |
| Regeneron Healthcare Solutions, Inc. | 88 | $111,018 |
| Mylan Specialty L.p. | 101 | $54,142 |
| Grifols USA, LLC | 101 | $49,267 |
| Sunovion Pharmaceuticals Inc. | 19 | $13,666 |
| Pfizer | 17 | $13,228 |
| Viatris Specialty LLC | 24 | $7,813 |
| AstraZeneca | 58 | $1,721 |
| Sanofi | 25 | $853 |
| Grifols Shared Services North America, Inc. | 1 | $820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $321 |
| Merck | 6 | $317 |
| Actelion Pharmaceuticals US, Inc. | 2 | $279 |
| Insmed, Inc. | 16 | $266 |
| Regeneron | 1 | $126 |
| Inari Medical, Inc. | 1 | $117 |
| Electromed, Inc. | 8 | $109 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Mallinckrodt Enterprises LLC | 1 | $96 |
| Nabriva Therapeutics, PLC | 4 | $62 |
| Verona Pharma, Inc. | 2 | $53 |
| Liquidia Technologies, Inc. | 1 | $29 |
| United Therapeutics Corporation | 1 | $22 |
| 3b Medical, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$167,537
- DUPIXENT$110,374
- Yupelri$60,576
- Prolastin-C Liquid$41,755
- OFEV$35,990
- LONHALA MAGNAIR$13,460
- ELIQUIS$13,065
- ANORO ELLIPTA$9,165
- Prolastin-C$6,976
- ANORO$3,706
- STIOLTO RESPIMAT$952
- NUCALA$375
- AIRSUPRA$366
- UPTRAVI$279
- OPSUMIT$279
- BREZTRI$236
- WINREVAIR$125
- Arikayce$117
- FlowTriever$117
- ClotTriever$117
How this compares
$613,051 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 936 | $981,919 |
| OfevNintedanib Esylate | 38 | $469,122 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 17 | $167,730 |
| Breo ElliptaFluticasone/Vilanterol | 238 | $155,127 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 183 | $154,666 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 153 | $123,398 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 190 | $121,974 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 324 | $86,988 |
| Spiriva RespimatTiotropium Bromide | 101 | $84,291 |
| Pirfenidone | 14 | $56,280 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,065 | $49,089 |
| Qvar RedihalerBeclomethasone Dipropionate | 132 | $42,073 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $37,129 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 34 | $28,724 |
| Spiriva HandihalerTiotropium Bromide | 22 | $28,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $232,556 | $1,293,8051,398 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $126,023 | $704,112363 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,721 | $191,794268 claims |
| Grifols USA, LLCProlastin C | $49,267 | $167,73017 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick | $13 | $43,560150 claims |
| MerckDulera | $317 | $4,51613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Buffalo
- Carla FrederickBuffalo$972K
- M Jeffery MadorBuffalo$408K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.